UPMC-backed cancer immunotherapy developer BlueSphere Bio has attracted an initial $45.6m in series B funding towards a $105m target for its close.
BlueSphere Bio, a US-based immunotherapy developer backed by healthcare provider UPMC, attracted $45.6m in series B funding last month, the Pittsburgh Business Times has reported, citing a regulatory filing.
The company is targeting a $105m close and will use the capital to further develop its immunotherapy platform, TCXpress, which is aimed at diseases such as cancer. Its lead asset aims to boost patient outcomes in bone marrow transplants.
TCXpress is based on technology developed by chief scientific officer and co-founder…